CYP2E1-IN-1 (Compound 10) is an orally active inhibitor of cytochrome P450 2E1 (CYP2E1) with a dissociation constant (Kd) of 7.02 µM, an IC50 of 1.64 µM, and a Ki of 0.897 µM. It alleviates pancreatic damage by activating the Nrf2/HO-1 signaling pathway and inhibiting ROS production. CYP2E1-IN-1 demonstrates significant anti-inflammatory and antioxidant properties, effectively reducing inflammation and oxidative stress in severe acute pancreatitis (SAP). It is suitable for the study of SAP and other inflammation-related conditions.
